Abstract
Coronary artery ectasia (CAE) is characterized by abnormal coronary artery dilation, often linked to systemic inflammation. This study investigated the relationship between CAE and inflammatory markers—high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6)—and hypothesized that patient age significantly influences the efficacy of anti-inflammatory therapy. Analyzing 217 CAE patients across three age groups, researchers found that younger patients (≤50 years) exhibited higher baseline inflammation but also experienced the most significant reductions in inflammatory markers following six months of rosuvastatin treatment. These findings suggest that early intervention with statin therapy is particularly effective in younger populations.
Introduction
Coronary artery ectasia (CAE) involves a localized or diffuse dilation of the coronary arteries to at least 1.5 times the diameter of adjacent normal segments. While its pathophysiology is often associated with atherosclerosis, the precise mechanisms remain elusive. Emerging evidence highlights inflammation as a primary driver of the condition. Specifically, markers like Hs-CRP and IL-6 are elevated in CAE patients, yet clinical guidelines for managing this inflammation are not yet standardized. This study aimed to determine if rosuvastatin, a common HMG-CoA reductase inhibitor with known pleiotropic anti-inflammatory effects, works differently across various age demographics.
Methods and Cohort Selection
The study involved a prospective analysis of patients treated at three major medical centers in China between 2015 and 2019. From an initial screening of 6,542 patients undergoing coronary angiography, 302 were diagnosed with CAE, representing a 4.6% prevalence. After applying exclusion criteria (such as heart failure or renal dysfunction), 217 CAE patients were enrolled and compared against 73 normal controls (NC).
Participants were categorized into three age-based cohorts:
- CAE-A: Age ≤50 years (n=60)
- CAE-B: Age 50–70 years (n=83)
- CAE-C: Age >70 years (n=74)
All CAE patients received a daily dose of 10 mg rosuvastatin. Serum levels of Hs-CRP and IL-6 were measured at baseline and at a 6-month follow-up to assess treatment impact.
Key Insights: The Inflammation Signature
Statistical analysis confirmed that inflammatory markers are not merely associated with CAE but are independent predictors of the disease. Logistic regression identified Hs-CRP (OR=1.782, 95% CI: 1.124-2.014) and IL-6 (OR=1.584, 95% CI: 1.112-1.986) as significant indicators.
A notable finding was the "Youth Paradox": the youngest group (CAE-A) presented with the highest baseline levels of inflammation (Hs-CRP: 32.3 mg/L) compared to the oldest group (CAE-C: 22.5 mg/L). This suggests that in younger patients, CAE may be driven by a more acute or "primed" immune response, whereas older patients may experience more chronic, low-grade inflammation.
Age-Dependent Treatment Efficacy
While rosuvastatin successfully reduced inflammatory markers across all age groups, the magnitude of the reduction was significantly higher in younger patients. This indicates that the inflammatory component of CAE in younger individuals is more responsive to pharmacological intervention.
As shown in the data, the reduction in Hs-CRP for the youngest group was approximately 15.1 mg/L (~47% decrease), while the oldest group saw a reduction of only 4.5 mg/L (~20% decrease). Similar trends were observed for IL-6, where the youngest cohort saw a reduction nearly three times greater than that of the oldest cohort (5.9 pg/dL vs. 1.9 pg/dL).
Conclusion
The study concludes that rosuvastatin is an effective anti-inflammatory agent for CAE patients, but its benefits are age-dependent. The heightened responsiveness in younger patients suggests a critical window for early intervention. In older patients, the persistence of inflammation despite therapy may indicate that arterial wall damage becomes less reversible over time. These results underscore the importance of early diagnosis and the prompt initiation of statin therapy to mitigate inflammatory progression in coronary artery ectasia.
Summary updated